Nova Eye USA Sales Growth Opportunity
Glaucoma Treatment Overview
Traditional medication treatment paradigm is
chronic medication use causes eye damage
limiting future treatment options.
Patients and surgeons are transitioning (1)
from medications in favour of minimally
invasive glaucoma surgery (MIGS) earlier in
the disease state.
MIGS are a solution to nonadherence and
can offer improved safety profile and better
certainty of outcome (1).
Advancements in diagnostic technologies
support earlier intervention.
Nova Eye is a key player in the global
MIGS market with its canaloplasty device,
iTrack™ Advance.
(1) Marketscope 2023 Glaucoma Surgical Device Market Report and Marketscope
2022 Glaucoma Surgical Device Market Report
•EEEE
Patient adherence to glaucoma
medications is poor
يع
Approx 50% of patients are non-compliant with
their medications
Approx 50% purposely discontinue their
medication(s) within 6 months
Nordstrom BL, Friedman DS, Mozaffari E, Quigley H, Walker AM. Persistence
and adherence with topical glaucoma therapy. Am J Ophthalmol.
2005;140(4): 598-606
Glaucoma surgical devices are
increasingly recognised as a viable
alternative to medications - and this
is the highest area of focus and
return for the patient, the physician
and the supplier.
nova-eye.com | 9View entire presentation